SMMT +1.85% in pre-mkt trading - earlier PR: Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western a

SMMT +1.85% in pre-mkt trading - earlier PR: Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study Link To Press Release